Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. [electronic resource]
Producer: 20140801Description: 292-304 p. digitalISSN:- 1699-7980
- Adenocarcinoma -- drug therapy
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antineoplastic Agents -- pharmacology
- Bone Density Conservation Agents -- pharmacology
- Bone Neoplasms -- complications
- Clinical Trials, Phase III as Topic
- Denosumab
- Diphosphonates -- pharmacology
- Double-Blind Method
- Forecasting
- Fractures, Spontaneous -- etiology
- Humans
- Imidazoles -- pharmacology
- Male
- Models, Biological
- Molecular Targeted Therapy
- Multicenter Studies as Topic
- Neoplasm Proteins -- antagonists & inhibitors
- Practice Guidelines as Topic
- Prostatic Neoplasms -- pathology
- Quality of Life
- RANK Ligand -- antagonists & inhibitors
- Randomized Controlled Trials as Topic
- Receptor Activator of Nuclear Factor-kappa B -- physiology
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.